Episode 3.2: Ranting About Rituximab in Acute Lymphoblastic Leukemia
WolverHeme Happy Hour
00:00
Should We Give Retuximab to Anyone With BSL, ALL?
"I don't know that this should change our practice one way or the other," he says. "We need more data to say whether we should be giving retuximab still." The study enrolled BCR-able positive patients with CD20 expression on more than 20% of BSL-ALL cells.
Transcript
Play full episode
